NASDAQ$NRC
NRC Health · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
NRC Health's financial performance for Q2 2022 was announced, revealing a slight revenue increase but a decrease in operating income.
NRC Health reported a 2% increase in revenue to $37.3 million, while operating income decreased by 6% to $11.5 million compared to the same quarter in the previous year. The company is focusing on organic growth and innovation initiatives.
- Revenue increased by 2% to $37.3 million compared to Q2 2021.
- Operating income decreased by 6% to $11.5 million compared to Q2 2021.
- The first official contract was secured for the Human Understanding Program with Novant Health.
- The company increased resource allocation for innovation initiatives, marketing, and associate retention.
Headline financials
Revenue & EPS history
NRC · Revenue · Quarterly
$37.3M
Forward guidance
Forward-looking statements are based on current beliefs and expectations and are subject to risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.3%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+16.1%
Q3 2025
Best reaction
-19.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +7.9% | +16.0% | |
| Q4 2025 | -19.9% | -27.2% | -35.9% | |
| Q3 2025 | +16.1% | +17.0% | +51.2% | |
| Q2 2025 | +2.1% | +4.8% | +6.7% | |
| Q1 2025 | +7.0% | +7.6% | +20.2% | |
| Q4 2024 | -11.9% | -11.0% | -22.6% | |
| Q3 2024 | +2.6% | -2.1% | +4.5% | |
| Q2 2024 | -11.7% | -9.3% | -7.2% | |
| Q1 2024 | -15.3% | -11.6% | -23.7% | |
| Q4 2023 | +2.2% | +0.6% | +1.7% | |
| Q3 2023 | -1.9% | -0.3% | -1.1% | |
| Q2 2023 | +2.2% | -0.4% | -2.6% | |
| Q1 2023 | -8.3% | -5.2% | -1.2% | |
| Q4 2022 | +4.8% | +5.3% | -1.8% | |
| Q3 2022 | -13.5% | -8.3% | -3.5% | |
| Q2 2022 | -4.1% | -7.4% | -12.8% | |
| Q1 2022 | -5.3% | -3.6% | +5.0% | |
| Q4 2021 | -1.5% | -4.5% | -4.7% | |
| Q3 2021 | +6.7% | +6.7% | -8.1% | |
| Q2 2021 | -0.8% | -0.2% | +1.6% | |
| Q1 2021 | -10.2% | -5.1% | -7.0% | |
| Q4 2020 | -0.7% | -3.9% | +0.3% | |
| Q3 2020 | +1.8% | -0.1% | -7.8% | |
| Q2 2020 | -4.1% | -1.0% | -3.0% | |
| Q1 2020 | +4.6% | +10.3% | +12.7% | |
| Q4 2019 | +0.3% | +1.8% | -36.0% | |
| Q3 2019 | -0.4% | +0.2% | +7.5% | |
| Q2 2019 | +3.0% | +2.6% | +1.0% | |
| Q1 2019 | +7.1% | +13.1% | +26.5% | |
| Q4 2018 | +0.6% | +2.7% | +0.2% | |
| Q3 2018 | +3.5% | +2.4% | +4.8% | |
| Q2 2018 | -0.3% | -0.3% | +2.4% | |
| Q1 2018 | +7.3% | +5.5% | +5.4% | |
| Q4 2017 | -7.4% | -7.9% | -9.7% | |
| Q3 2017 | -10.1% | -11.5% | -7.7% | |
| Q2 2017 | +0.9% | +1.7% | +9.9% | |
| Q1 2017 | +0.8% | -3.4% | -3.0% | |
| Q4 2016 | -3.0% | -4.9% | +0.5% | |
| Q3 2016 | -4.6% | -1.0% | +5.2% | |
| Q2 2016 | +0.3% | +2.3% | +2.2% | |
| Q1 2016 | +2.0% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +0.9% | — | — | |
| Q2 2014 | +3.8% | — | — | |
| Q1 2014 | +3.9% | — | — | |
| Q4 2013 | +5.1% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q2 2013 | -1.2% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q4 2009 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro